|
 Our Halogen-Enriched Fragment Library comprises 708 brominated fragments that can explore binding sites for favorable halogen bond interactions to identify unique binding modes that are complementary to those obtained from classical fragment-based screening.
|
|
Read more...
|
|
|
The OTAVA G9a Targeted Library comprises 561 carefully curated small molecules aimed at modulating the activity of histone methyltransferase G9a (EHMT2)—a master regulator of transcriptional repression through histone H3 lysine 9 (H3K9) methylation. This collection provides a powerful resource for researchers exploring epigenetics-driven mechanisms in cancer, neurodegeneration, inflammation, and stem cell reprogramming.
|
|
Read more...
|
|
Phenotypic drug discovery is successful strategy that allows to identify substances (small molecules, peptides etc.) which alter the phenotype of cells, tissues or whole organisms in a desired manner.
|
|
Read more...
|
|
|
Histone deacetylase 1 (HDAC1; also known as GON-10, RPD3, or KDAC1) is a key epigenetic regulator involved in chromatin remodeling and gene expression. Aberrant HDAC1 activity has been implicated in tumorigenesis, and it is widely recognized as a high-value target for cancer therapy due to its role in promoting oncogenic transcriptional programs.
The mechanistic target of rapamycin (mTOR; also referred to as FRAP1, RAFT1, or RAPT1) is a central serine/threonine kinase that integrates nutrient and growth factor signals to regulate cell growth, proliferation, metabolism, and autophagy. Hyperactivation of mTOR signaling is a hallmark of various malignancies, contributing to uncontrolled tumor cell survival and resistance to therapy.
|
|
Read more...
|
Embark on a new era of drug discovery as OTAVA’s CHEMRIYA™ Virtual Chemical Space integrates with CHEESE Search, the advanced AI-powered platform by Deep MedChem.
Unparalleled Chemical Diversity:
Access a subset of CHEMRIYA™, a next-generation virtual chemical space tailored for hit expansion, hit-to-lead, and lead optimization.
|
|
Read more...
|
|
|
|
|
|
|
Page 2 of 15 |
HOME
Overview
